Phio Pharmaceuticals Corp. filed a Form 8-K on November 20, 2026, disclosing that it received a written notice from Nasdaq on November 16, 2026, indicating its common stock had failed to meet the minimum bid price requirement for the prior 30 consecutive business days.
Key Highlights
- Notice received November 16, 2026: Nasdaq's Listing Qualifications Department notified Phio Pharmaceuticals that its common stock closing bid price had been below $1.00 per share for the previous 30 consecutive business days.
- Rule cited: The notice references Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.
- No immediate listing impact: According to the filing, "The Notice has no immediate effect on the Nasdaq listing or trading of the Company's common stock."
- 180-day cure period: Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, or until May 17, 2027, to regain compliance.
- Compliance threshold: To regain compliance, the closing bid price must reach at least $1.00 per share for a minimum of 10 consecutive business days before the deadline.
- Company response: The company disclosed it "intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance."
Phio Pharmaceuticals Discloses Nasdaq Bid Price Deficiency and Cure Timeline
Trading on NASDAQ:PHIO (Nasdaq Capital Market) continues without interruption following the notice, as the company reported in its Form 8-K filing dated November 20, 2026. The written notice, issued by Nasdaq's Listing Qualifications Department on November 16, 2026, stated that Phio's common stock closing bid price had remained below the $1.00 per share minimum for the 30 consecutive business days preceding the notice, triggering the notification requirement under Nasdaq Listing Rule 5550(a)(2).
According to the filing, the company has been granted an initial cure period of 180 calendar days running through May 17, 2027, consistent with Nasdaq Listing Rule 5810(c)(3)(A). During this period, if the closing bid price of Phio's common stock closes at $1.00 per share or higher for at least 10 consecutive business days, Nasdaq will notify the company that it has achieved compliance. The filing does not specify any particular action the company has already taken to address the deficiency, stating only that it will evaluate available options.
The filing includes forward-looking statements, which the company characterizes as subject to material differences between anticipated and actual outcomes. The company disclosed it "does not assume any obligation to update forward-looking statements as circumstances change, except as required by securities laws." The Form 8-K was signed by Robert J. Bitterman, President and Chief Executive Officer, on November 20, 2026.
What Was Disclosed
Phio Pharmaceuticals disclosed receipt of a Nasdaq bid price deficiency notice dated November 16, 2026, covering a failure to meet the $1.00 per share minimum for 30 consecutive business days, with a compliance deadline of May 17, 2027.



Please wait processing your request...